Hoth Therapeutics, Inc.

HOTH

US44148G2049

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 07:34:53 23/05/2024 pm IST			5-day change	1st Jan Change
1.175 ^USD	-2.08%		-0.84%	-18.06%

28/03	Hoth Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
19/03	Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	MT

Hoth Therapeutics Announces the Appointment of Dr. William Weglicki, M.D. to Scientific Advisory Board

December 17, 2019 at 09:30 pm IST

Hoth Therapeutics, Inc. announced the addition of Dr. William Weglicki, M.D. to the Company's Scientific Advisory Board. While serving on the Board, Dr, Weglicki will oversee Hoth's Aprepitant Program under its Scientific Research Agreement with the George Washington University ("GW").

Latest news about Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	19/03	MT
Hoth Therapeutics, Inc. Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ	19/03	CI
HC Wainwright Starts Hoth Therapeutics With Buy Rating, $4 Price Target	05/02	MT
Hoth Therapeutics Shares Rise 14% After FDA Clearance for HT-001 Trial Amendments	18/01	DJ
Hoth Therapeutics Receives FDA Approval to Expand HT-001 Clinical Trial to Treat Severely III Patients	18/01	CI
Hoth Therapeutics Gets University of Miami Approval to Enroll Patients in Skin Toxicities Treatment Trial; Shares Rise	27/12	MT
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial for Cancer Patients of HT-001 At University of Miami	27/12	CI
Hoth Therapeutics Announces Successfully Completed Manufacturing of its Cancer Fighting HT-KIT for Ind-Enabling Studies	05/12	CI
Hoth Therapeutics to Advance HT-KIT After Positive Feedback From FDA	14/11	MT
Hoth Therapeutics, Inc. Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT	14/11	CI
Hoth Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients	02/23/02	CI
Hoth Therapeutics Completes $2.89 Million Registered Direct Stock Offering	16/23/16	MT
Hoth Therapeutics, Inc. announced that it has received $2.892449 million in funding	15/23/15	CI
EF Hutton Cuts Hoth Therapeutics Price Target to $7.50 From $12, Maintains Buy Rating	14/23/14	MT
Hoth Therapeutics Prices Registered Direct Offering at $2.63 per Share	14/23/14	MT
Hoth Therapeutics, Inc. Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia	13/23/13	CI
Hoth Therapeutics, Inc. announced that it expects to receive $2.892449 million in funding	13/23/13	CI
Hoth Therapeutics Seeks FDA Meeting to Discuss HT-KIT Cancer Drug Program	11/23/11	MT
EF Hutton Assumes Hoth Therapeutics at Buy With $14 Price Target	23/23/23	MT
Hoth Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	12/23/12	CI
Hoth Therapeutics, Inc. Doses First Patient in its Phase 2a Clinical Trial of HT-001 for Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors	25/23/25	CI
Hoth Therapeutics Says FDA Approved Protocol Change in Trial of Treatment for Cancer Therapy-Induced Skin Disorders	19/23/19	MT
Hoth Therapeutics, Inc. Receives Protocol Approval for HT-001 Cancer Therapeutic	19/23/19	CI

Chart Hoth Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimerâs or other neuroinflammatory diseases (HT-ALZ). It also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The Company also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.2 USD

Average target price

5.5 USD

Spread / Average Target

+358.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HOTH THERAPEUTICS, INC.	-18.06%	58.67L
ELI LILLY AND COMPANY	+37.84%	72TCr
NOVO NORDISK A/S	+33.96%	59TCr
JOHNSON & JOHNSON	-2.90%	37TCr
MERCK & CO., INC.	+20.22%	33TCr
ABBVIE INC.	+2.55%	28TCr
ASTRAZENECA PLC	+16.91%	24TCr
NOVARTIS AG	+9.51%	21TCr
ROCHE HOLDING AG	-4.74%	21TCr
PFIZER, INC.	+0.83%	17TCr

Other Pharmaceuticals

Hoth Therapeutics, Inc.

Equities

HOTH

US44148G2049

Pharmaceuticals

Hoth Therapeutics Announces the Appointment of Dr. William Weglicki, M.D. to Scientific Advisory Board

Latest news about Hoth Therapeutics, Inc.

Chart Hoth Therapeutics, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals